Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 4/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313186 | 0.85 | ABL1 (0.36) | ALDH1A1LMNAABL1AXLSLC9A1 | |
| SCHEMBL4452242 | 0.85 | SLC9A1 (0.48) | ALDH1A1MAPK1LMNASLC9A1MAPT | |
| SCHEMBL6321925 | 0.84 | MAPT (0.38) | ALDH1A1MAPK1LMNAABL1AXL | |
| SCHEMBL6319630 | 0.84 | ALDH1A1 (0.41) | ALDH1A1MAPK1LMNAABL1AXL | |
| SCHEMBL4452237 | 0.78 | ALDH1A1 (0.43) | ALDH1A1MAPK1LMNAMAPTPOLB | |
| SCHEMBL4458516 | 0.77 | SLC9A1 (0.49) | ALDH1A1LMNAABL1AXLSLC9A1 | |
| SCHEMBL6312734 | 0.77 | NR4A3 (0.49) | ALDH1A1MAPK1LMNAMAPTPOLB | |
| Hydrochloric Acid SCHEMBL6313517 | 0.77 | SLC9A1 (0.48) | ALDH1A1LMNAABL1AXLSLC9A1 | |
| SCHEMBL6314449 | 0.76 | HPGD (0.46) | ALDH1A1MAPK1MAPTMAPK14 | |
| Trifluoroacetic Acid SCHEMBL6321915 | 0.75 | MAPT (0.45) | ALDH1A1MAPK1LMNAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | ALDH1A1 642/4885MAPK1 1899/4885LMNA 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.